Abstract | AIMS: METHODS: A retrospective analysis was conducted of 185 osteosarcoma patients treated with the four drugs mentioned above. A total of 93 patients received the Italian therapeutic treatment (IOR-OS/N-5: Instituto Ortopedic Rizzoli-Section of Osteosacorma/ Neoadjuvant chemotherapy-5) and the remaining 92 patients received the therapeutic treatment optimized by our department. We compared the efficacy and toxic side effects of these two therapies. RESULTS: The limb salvage rates, 3-year recurrence rates and 3-year metastasis rates of IOR-OS/N-5 and our optimized treatment were 52.7 and 58.7%; 20.9 and 11.4% and 44.1 and 27.2%, respectively. The 3-year survival rates and the 3-year disease-free survival rates of IOR-OS/N-5 and our optimized treatments were 62.4 and 78.4%; and 53.6 and 67.8%, respectively. Overall survival and disease-free survival rates were significantly different between these two treatments (P = 0.032 and 0.024, respectively). Liver function with degree III and IV damage accounted for 35.2 and 16.6% of the total adverse reactions in the IOR-OS/N-5 and our optimized treatment groups, respectively. Degree III-IV neutropenia accounted for 22.6 and 40.0%, respectively, in the IOR-OS/N-5 and optimized treatments. CONCLUSION: The optimization of MTX, DDP, DOX and IFO based on Chinese patients' physiology increased the tolerance and efficacy for the treatment of osteosarcoma.
|
Authors | Feng Lin, Qiong Wang, Wenxi Yu, Lina Tang, Shuier Zheng, Yuanjue Sun, Zan Shen, Yang Yao, Yang Dong |
Journal | Asia-Pacific journal of clinical oncology
(Asia Pac J Clin Oncol)
Vol. 7
Issue 3
Pg. 270-5
(Sep 2011)
ISSN: 1743-7563 [Electronic] Australia |
PMID | 21884438
(Publication Type: Journal Article)
|
Copyright | © 2011 Blackwell Publishing Asia Pty Ltd. |
Chemical References |
- Doxorubicin
- Cisplatin
- Ifosfamide
- Methotrexate
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Neoplasms
(drug therapy, pathology, surgery)
- Child
- Child, Preschool
- China
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Neoadjuvant Therapy
- Osteosarcoma
(drug therapy, pathology, surgery)
- Retrospective Studies
- Young Adult
|